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Background: The focus of this study was to characterize a novel biomarker for cystic ﬁbrosis (CF) that could reﬂect exacerbations of the disease
and could be useful for therapeutic stratiﬁcation of patients, or for testing of potential drug treatments. This study focused exclusively on a protein
complex containing alpha-1 antitrypsin and CD16b (AAT:CD16b) which is released into the bloodstream from membranes of pro-inﬂammatory
primed neutrophils.
Methods: Neutrophil membrane expression and extracellular levels of AAT and CD16b were quantiﬁed by ﬂow cytometry, Western blot analysis
and by 2D-PAGE. Interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha) and AAT:CD16b complex were quantiﬁed in CF plasma (n=38),
samples post antibiotic treatment for 14 days (n=10), chronic obstructive pulmonary disease (n=10), AAT deﬁcient (n=10) and healthy control
(n=14) plasma samples by ELISA.
Results: Cell priming with IL-8 and TNF-alpha caused release of the AAT:CD16b complex from the neutrophil cell membrane. Circulating plasma
levels of IL-8, TNF-alpha and AAT:CD16b complex were signiﬁcantly higher in patients with CF than in the other patient groups or healthy con-
trols (Pb0.05). Antibiotic treatment of pulmonary exacerbation in patients with CF led to decreased plasma protein concentrations of AAT:CD16b
complex with a signiﬁcant correlation with improved FEV1 (r=0.81, P=0.003).
Conclusion: The results of this study have shown that levels of AAT:CD16b complex present in plasma correlate to the inﬂammatory status of
patients. The AAT:CD16b biomarker may become a useful addition to the clinical diagnosis of exacerbations in CF.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Alpha-1 antitrypsin; CD16b; Infection; Inﬂammation; Pulmonary exacerbation1. Introduction
Cystic fibrosis is an autosomal recessive condition and al-
though a multi-organ disorder, end-stage lung disease with
chronic bacterial infection is the major cause of morbidity and⁎ Corresponding author. Tel.: +353 1 8093877; fax: +353 1 8093808.
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doi:10.1016/j.jcf.2011.09.010mortality in affected individuals [1]. The pathogenesis of lung
disease induced by CF is a direct result of decreased chloride
secretion and hyper-absorption of sodium, resulting in the re-
tention of dehydrated mucus within the airways [2]. This thick-
ened mucus provides an ideal environment for bacterial
infection in the respiratory tract. Staphylococcus aureus
(S. aureus) is the major bacterial pathogen in early years but
subsequently Pseudomonas aeruginosa (P. aeruginosa) be-
comes the prominent pathogen in adult patients [3,4]. Addingby Elsevier B.V. All rights reserved.
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tum samples including Prevotella, S. saccharolyticus, Peptos-
treptococcus prevotii and Actinomyces have been detected
[5,6]. Intravenous (i.v.) antibiotics are normally used for acute
infective exacerbations with efficacy assessed by monitoring
respiratory function, body weight and circulating markers of
systemic inflammation [7].
In addition to ineffective mucociliary and cough clearance,
persistent expression of inflammatory cytokines and chemo-
kines plays a major role in the pathogenesis of chronic lung dis-
ease [8], leading to recruitment and activation of neutrophils in
the CF airways [9]. Longitudinal and prospective studies of in-
fants with CF and also within an animal model with mutated
CFTR genes, demonstrate that airway inflammation follows re-
spiratory infection [10]. Thus an increasing volume of clinical
data supports the use of early antimicrobial treatment to inhibit
[11] or delay [12] bacterial infection and to achieve decreased
hospitalization and improved patient survival. For this reason
there has been increased interest in the use of infective exacer-
bations (frequency and resolution) as an outcome measure in
clinical trials and sensitivity to treatment. However, while
there are a number of criteria put forward to define an exacerba-
tion [13–16] variability among parameters exists [17]. More-
over, as new agents are investigated in clinical trials and new
therapeutic targets are identified, it is becoming increasingly
important to accurately define the clinical signs and symptoms
of pulmonary exacerbations and to define objective markers of
infection [18].
Inflammatory biomarkers represent a solution to the varia-
tion in the clinical criteria defining exacerbations in CF. Thus
far identified biomarkers indicative of increased pulmonary in-
flammation with P. aeruginosa infection include serum levels
of G-CSF [19] and matrix metalloproteinase-1, -8 and -9 [20].
Alternatively levels of cytokines including IL-8 [21], neutrophil
released elastase [22], myeloperoxidase [23] and cathepsin B
and S [24] have been evaluated as markers of pulmonary exac-
erbation in sputum samples. However, one aspect of neutrophil
physiology which has largely been overlooked is pre-activation
or priming of the circulating cell. Neutrophil priming is a pre-
requisite for homing to the lung and can be used as read-out
for the in vivo action of pro- and anti-inflammatory cytokines.
Consequently, we hypothesized that markers of neutrophil
priming in the systemic compartment would serve as an
early read-out for pulmonary exacerbation in CF and should
be normalized upon optimal treatment. Recently we have
shown that the acute phase protein alpha-1 antitrypsin, is
bound to the circulating neutrophil via interaction with the
glycosylphosphatidyl-inositol (GPI) linked membrane protein
CD16b (FcγRIIIb) [25]. Moreover, soluble immune complex
(sIC) primed the circulating neutrophil to release AAT from
the cell membrane within a protein complex with CD16b.
Within the present study we investigated the potential of neu-
trophil released AAT:CD16b protein complex to serve as a po-
tential marker of infective inflammation and resolution of
pulmonary exacerbation in adult patients with CF. Some of
the results of this study have been previously reported in the
form of an abstract [26].2. Materials and methods
2.1. Chemicals and reagents
All chemicals and reagents were endotoxin free and were
purchased from Sigma-Aldrich unless indicated otherwise.
2.2. Patient groups
Four patient groups and healthy control volunteers were
recruited to this study as follows: 1: Asymptomatic alpha-1 anti-
trypsin deficient individuals (AATD) not receiving therapy were
recruited from the Irish Alpha-1 Antitrypsin Deficiency Registry
(n=10, mean age 43.95±8.53). AATD patients had plasma AAT
levels b11 μMand were clinically stable with a forced expiratory
volume in 1 s (FEV1) of 98.2%±17.48% predicted. 2: Adult pa-
tients with COPD (n=10) and a history of smoking were
recruited as previously described [27]. 3: Patients with CF
(n=38, mean age 26.8±5.9) were genotyped for cystic fibrosis
transmembrane conductance regulator mutations. Treatment of
an acute bacterial exacerbation in 10 patients with CF involved
i.v. administration of colomycin (2 million units i.v. 3 times
daily (t.d.s)), piperacillin/tazobactam (4.5 g i.v. t.d.s.), flucloxa-
cillin (2 g i.v. 4 times daily (q.d.s)), meropenem (2 g i.v. t.d.s.)
and/or ciprofloxacin (400 mg i.v. 2 times daily (b.d.)). An exacer-
bation was defined by previously validated criteria [28]. 4: All
non-CF bronchiectasis patients (n=6, mean age 64±6.7, mean
% FEV1 of 59% predicted) were recruited from a specialized
non-CF bronchiectasis clinic and had no evidence of an exacerba-
tion at the time of recruitment. 5: Control volunteers (n=14,
mean age 34.72±3.17) had no respiratory symptoms and were
not onmedication. All participants gave written informed consent
to participate in the study, which was approved by Beaumont
Hospital Ethics Committee.
2.3. Neutrophil isolation and membrane fractionation
Neutrophils were purified from whole blood and membranes
were isolated as previously described employing sucrose densi-
ty ultracentrifugation [25]. The methodology for flow cytome-
try, proteomic analysis, SDS–PAGE and Western blotting of
neutrophil plasma membranes can be found within the Supple-
mental materials and methods.
2.4. Enzyme linked immunosorbent assays (ELISAs)
The concentration of IL-8 or TNF-alpha in plasma samples
was measured by enzyme linked immunosorbent assay
(ELISA), conducted in accordance with the manufacturer's in-
structions (R&D Systems). For the detection of AAT:CD16b
complex within plasma samples of healthy control, AATD or
patients with CF, 5 μg/ml of specific mouse anti-CD16b
(R&D systems) was employed as a capture antibody and
50 ng/ml of polyclonal goat anti-AAT specific antibody
(Abcam) as a detection antibody, followed by an anti-goat
IgG conjugated to HRP. Prior to each assay, wells from Nunc
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suspended in Buffer A (15 mM Na2CO3 and 35 mM
NaHCO3, pH 9.3) over night at 4 °C. The wells were subse-
quently washed in Buffer A, blocked with bovine serum albu-
min (BSA; 1% w/v) for 1 h and exposed to patient plasma
(100 μl). As the ELISA was based on quantification of AAT
complexed to CD16b that is captured by the anti-CD16b anti-
body, serial dilutions of purified human AAT were simulta-
neously coated in triplicate in the Nunc 96-well microtiter
plate to establish a standard curve as previously described
[29]. Controls included all reagents except capture, detection
antibody or biotinylated secondary antibody.
2.5. Statistical analysis
All experiments were performed a minimum of three times
and results expressed as means±standard error of the mean.
The data was analyzed with the GraphPad Prism version 4.03
for Windows (GraphPad Software, USA). Continuous data
were tested for normality (1 sample Kolmogorov–Smirnoff
test) and where normal were compared using an unpaired stu-
dent t-test. Differences between data sets were considered sta-
tistically significant with a P-value≤0.05. Quantification of
protein abundance was determined using the biological varia-
tion analysis module of Decyder™ using ANOVA-1 analysis
for comparing across the different groups (healthy controls,
non-CF bronchiectasis and CF samples pre- and post-
antibiotic treatment). Differential expression was defined asFig. 1. Pro-inflammatory mediators cause release of AAT and CD16b from the neutr
(B), CD16b on membranes of un-stimulated control neutrophils (con) or in response
(filled). Experiments presented were performed in triplicate on three consecutive days
course of TNF-alpha (10 ng/2×107 cells) induced extracellular release of AAT and C
rabbit and goat polyclonal antibody against AAT and CD16b respectively. D: Quant
the presence or absence of TAPI-1. TAPI-1 significantly reduced release of AAT angreater than 1.5-fold change in expression with a P-
value≤0.05.
3. Results
3.1. Proinflammatory mediators cause release of AAT and
CD16b from neutrophil membranes
We have previously shown that exposure of neutrophils to
sIC causes release of AAT and CD16b from the neutrophil
membrane in a complex form [25]. To build on this background
information the effect of the proinflammatory stimulus IL-8, on
release/shedding of AAT and CD16b from the neutrophil
membrane was investigated. Neutrophils were primed with
IL-8 (10 ng/2×107 cells) and after 10 min of treatment a signif-
icant decrease in cell surface AAT was detected by flow cyto-
metry (control untreated mean fluorescence=50.98±0.67 and
IL-8 treated cells mean=17.62±0.06, Pb0.05) (Fig. 1A).
Moreover, the observed decrease in membrane AAT corre-
sponded with a reduction in CD16b expression (control
untreated mean fluorescence=38.75±0.11 and IL-8 treated
cells mean=19.22±0.05, Pb0.05) (Fig. 1B). Furthermore, we
have previously shown that release of AAT:CD16b complex
from the cell membrane in response to sIC involves surface
sheddase activity including ADAM-17 [25]. We therefore
investigated whether ADAM-17 activity was required for con-
comitant release of AAT with CD16b in response to TNF-
alpha. This was confirmed when cells were primed with TNF-ophil membrane. FACS analysis showing membrane expression of (A), AAT or
to IL-8 (10 ng/2×107 cells). The isotype control antibody is illustrated in black
. C: Representative immuno-blots (one of 3 separate experiments) showing time
D16b from neutrophils with or without TAPI-1 (10 μM). Experiments employed
ification of AAT and CD16b release from neutrophils treated with TNF-alpha in
d CD16b (*Pb0.05 compared to respective untreated sample).
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analyzed by Western blot for the presence of released CD16b
and AAT (Fig. 1C). TNF-alpha induced release of CD16b
and AAT at 5 and 10 min post exposure, an effect inhibited
by inclusion of the specific ADAM-17 inhibitor, TAPI-1
(10 μM) [30]. TAPI-1 prevented release of AAT and CD16b
in response to TNF-alpha and significantly reduced the extra-
cellular detectable level of the two proteins by approximately
80% at the 5 min time point (Pb0.05) (Fig. 1D). Collectively,
these results demonstrate that neutrophils primed by pro-
inflammatory mediators including IL-8 and TNF-alpha, rapidly
release AAT and CD16b from the neutrophil membrane.Fig. 2. Protein levels of inflammatory molecules and AAT:CD16b complex
in plasma from COPD, AATD, CF and healthy controls. ELISA analyses of IL-
8 (pg/ml) (A), TNF-alpha (pg/ml) (B) orAAT:CD16b complex (ng/ml) (C) in plasma
from healthy (control; n=14), COPD (n=10), AATD (n=10) and CF (n=38) indi-
viduals. Statistical significance was analyzed by ANOVA, *Pb0.05.3.2. Increased levels of proinflammatory mediators and
CD16b:AAT complex in plasma from CF patients
Quantification of IL-8 by ELISA revealed significantly elevat-
ed levels of IL-8 in CF plasma compared to COPD and control
subjects (553.8±82.2 versus 249.9±26.2 and 168.3±51.2 pg/ml
plasma respectively, Pb0.05) (Fig. 2A). In accordance with re-
sults obtained for IL-8, significantly elevated levels of TNF-
alpha were measured in CF plasma compared to COPD and con-
trol subjects (10.43±2.12 versus 1.56±0.75 and 4.16±
1.02 pg/ml plasma respectively, Pb0.05) (Fig. 2B).Moreover, in-
dividuals with CFwere more likely to have elevated plasma levels
of AAT:CD16b compared to COPD and control groups (Fig. 2C).
Significantly higher levels of AAT:CD16b protein complex were
detected in CF patient plasma (6.47±0.65 ng/ml) compared
with results from the other groups (COPD=0.73±0.26,
AATD=0.01±0.005 and control=0.80±0.24; Pb0.05)
(Fig. 2C). This sandwich ELISA employed a detection antibody
to AAT and measured negligible levels of AAT:CD16b complex
in plasma of AATD individuals. Accordingly, this sample cohort
served as a negative control and a measure of accuracy of the
AAT:CD16b ELISA.
Next, we analyzed the correlation between levels of AAT:
CD16b and proinflammatory mediators (IL-8 and TNF-alpha)
within CF plasma. The combined IL-8 and TNF-alpha levels
in plasma showed a significant positive correlation with the
concentration of AAT:CD16b complex (n=62, r=0.4223;
P=0.0001; Fig. 3). Taken together these results illustrate a
novel correlation between increased pro-inflammatory media-
tors and AAT:CD16b complex plasma levels.3.3. Levels of AAT:CD16b complex in CF patients decrease
post antibiotic therapy
To determine if levels of AAT:CD16b complex in plasma
could reflect the inflammatory states of individuals with CF,
we carried out analysis of patients plasma pre- and post-
antibiotic therapy. Patients were treated for an acute microbial
exacerbation related to P. aeruginosa and/or S. aureus bacterial
infection predominately. As illustrated in Table 1, an improve-
ment in spirometry measurements was observed in most cases
following treatment (pretreatment FEV1% predicted mean of
35.20, range 23–48; post-treatment mean 43.60, range 24–65).CF plasma samples before and after intravenous antibiotic
therapy were quantified for AAT:CD16b complex by ELISA.
Of the 10 patient samples analyzed, levels of AAT:CD16b de-
creased after the administration of antibiotic therapy with the
exception of 2 (Fig. 4A). These latter two patients were deemed
nonresponsive to treatment and clinical symptoms did not im-
prove with therapy, as measured by a decreased increment in
FEV1 (Table 1: CF4 and CF6).
Proteomic analysis was carried out to evaluate the expres-
sion of the AAT:CD16b complex on isolated neutrophil mem-
branes pre- and post-therapy. The 6 patients with CF selected
for proteomic analysis were representative of the whole group
(same degree of exacerbation) and controls for this experiment
included membrane samples from 6 non-CF bronchiectasis
Fig. 3. Positive correlation between AAT:CD16b protein complex and proin-
flammatory mediators in plasma. The correlation between IL-8 (○) and TNF-
alpha (●) and plasma AAT:CD16b protein complex levels was deemed signif-
icant when α=0.05 (Pearson r=0.42, Pb0.0001, R2=0.17).
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treatment modulated expressions of multiple protein spots pre-
sent on analytical 2-D gel images compared to the samples col-
lected without treatment on day 0. In total, ~750 spots were
detected on the 2-D analytical gels by DeCyder software.
When comparing the membrane protein spots on the gels
from day 0 with that of 14-day post treatment and control mem-
branes, 36 spots showed differential expression. Two of these
spots were down-regulated in CF samples on day 0, while
they were increased at least 1.5-fold in both the membrane sam-
ples from the 14-day-treated CF patients and the samples from
the control persons (non-CF bronchiectasis and healthy control
membranes, Pb0.05 by ANOVA-1). Those 2 unknown spots
were excised from the gels and identified as AAT and CD16b
by LC-MS/MS (accession number gi994572 and gi703025, re-
spectively). Densitometry of Western blots of CF membranes
for AAT and CD16b pre- and post-antibiotic therapy, con-
firmed proteomic results (Fig. 4B and C) and indicated signifi-
cantly increased expression of AAT and CD16b (P=0.01 and
P=0.05 respectively) on CF neutrophil membranes post antibi-
otic treatment. Of clinical importance, post antibiotic treatment,
a positive correlation was found between % increase in FEV1
and reduced circulating plasma levels of AAT:CD16b (n=10,
r=0.84, pb0.005; Fig. 5). Collectively these results indicate
that treatment of an exacerbation with antibiotic therapy in
CF results in decreasing levels of plasma AAT:CD16b, with aTable 1
Individual patient data.
Age (year) Bacterial infection
CF1 25 P. aeruginosa (mucoid and non-mucoid), Candida
CF2 34 S. aureus; P. aeruginosa (non-mucoid)
CF3 30 P. aeruginosa (mucoid and non-mucoid), Candida
CF4 22 S. aureus;P. aeruginosa (mucoid and non-mucoid)
CF5 21 P. aeruginosa (mucoid and non-mucoid)
CF6 19 P. aeruginosa (mucoid and non-mucoid), ESBL, Aspergillus
CF7 25 P. aeruginosa (mucoid)
CF8 22 S. aureus; P. aeruginosa (non-mucoid)
CF9 31 P. aeruginosa (mucoid and non-mucoid)
CF10 28 P. aeruginosa (mucoid and non-mucoid)
P. aeruginosa=Pseudomonas aeruginosa; S. aureus=Staphylococcus aureus; ESBLcorresponding increase in the level of membrane bound com-
plex and improved FEV1.
4. Discussion
Pulmonary exacerbations are important contributors to mor-
bidity and are associated with lung function decline over 1 year
in CF [31]. However, a foremost obstacle in investigating the
processes and functional changes associated with CF exacerba-
tions is the lack of a clear diagnostic standard. A circulating
biomarker of neutrophil priming prior to airway neutrophil mi-
gration and activation would serve as a specific biomarker for
the early detection of CF exacerbations and the subsequent re-
sponse to antibiotic treatment. In this study we have combined
well-defined clinical groups and demonstrated that plasma
levels of neutrophil released AAT:CD16b complex correlate
with circulating plasma levels of pro-inflammatory mediators.
Post antibiotic treatment of CF pulmonary exacerbation, we ob-
served an increase in FEV1 and a corresponding decrease in
plasma protein concentration of AAT:CD16b complex. These
results indicate that the AAT:CD16b plasma biomarker effec-
tively reflects exacerbations of the disease.
Research within this area has identified a number of possible
biomarkers of CF exacerbation. For example, by employing a
proteomic approach of induced sputum from adult patients
with CF, proteolytic degradation and glycosylation of mucins
MUC5B and MUC5AC [32] or degradation of IgG and alpha-
1 antitrypsin, were proposed as predictors of CF lung exacerba-
tion [23]. By immunometric techniques sputum levels of IL-
8 have also been shown to significantly alter following treat-
ment of CF exacerbations with antibiotic therapy, suggestive
of a noninvasive outcome measure to assess response to therapy
in CF patients [33]. However, Downey et al. (2007) did not find
a reduction in sputum IL-8 levels [7], indicating that sputum IL-
8 correlates poorly with lung function, thus questioning the
suitability of IL-8 as a reliable biomarker of CF exacerbations.
Therefore as an alternative to using sputum, serum samples
from patients with CF have also been compared with control
sera in order to recognize protein expression profiles specific
to CF during an exacerbation. Compared to healthy controls,
matrix metalloproteinase (MMP-1, -8 and -9) and G-CSF
serum levels were elevated in adult patients with CF and corre-
lated with pulmonary exacerbation and antibiotic treatmentAntibiotic treatment Pre-%FEV1 Post-%FEV1
Colomycin, piperacillin/tazobactam 34 40
Colomycin, piperacillin/tazobactam, flucloxacillin 45 65
Colomycin, piperacillin/tazobactam, flucloxacillin 26 43
Ceftazidime, flucloxacillin, meropenem 26 24
Ciprofloxacin, colomycin 28 32
Meropenem, colomycin 48 46
Ciprofloxacin, meropenem 47 49
Colomycin, piperacillin/tazobactam, 38 44
Colomycin, piperacillin/tazobactam, flucloxacillin 37 65
Colomycin, piperacillin/tazobactam 23 28
=Extended spectrum beta-lactamase bacteria.
Fig. 5. Positive correlation between reduced plasma levels of AAT:CD16b pro-
tein complex and improved FEV1 post antibiotic treatment. Correlation be-
tween FEV1 (% increase) after 2 weeks antibiotic treatment of individuals
with CF (n=10) and changes in plasma levels of AAT:CD16b (ng/ml plasma).
Fig. 4. Levels of AAT:CD16b complex decrease in plasma samples post antibi-
otic therapy. A; ELISA quantification of AAT:CD16b complex (ng/ml) plasma
levels before (Pre) and 14 days after (Post) antibiotic treatment of patients with
CF (n=10). Two nonresponsive patients had higher levels of AAT:CD16b com-
plex (dashed line) B and C; Membrane expression of CD16b (B) or AAT (C) on
CF neutrophils before (Pre) and after (Post) antibiotic therapy. The data pre-
sented were calculated using constants obtained of Western blot densitometry
values. Each measurement is the mean±S.E (*Pb0.05).
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vascular endothelial growth factor [35] have also been suggested
as serum markers of acute infectious exacerbations and to de-
crease significantly post treatment of an exacerbation. Moreover,
while CF exacerbations were not shown to modulate neutrophil
function [36], neutrophil derived proteins including myeloperox-
idase in peripheral blood appeared to reflect inflammatory
changes post antibiotic treatment [37]. Myeloperoxidase howev-
er is a component of neutrophil primary/azurophilic granules and
peroxidase exocytosis is a tightly regulated process. Within thepresent study, rather than identifying markers of neutrophil acti-
vation we have focused on a plasma marker of neutrophil pre-
activation or priming. Priming can be induced by pro-
inflammatory stimuli which are increased in an in vivo state of
CF exacerbation and which prepare the neutrophil for a state of
readiness preceding complete activation. The fundamental mech-
anism leading to a primed response involves increased levels of
cytosolic calcium [38], upregulated tyrosine phosphorylation
[39] and cytoskeletal rearrangements [40]. Pseudomonas algi-
nate [41], TNF-alpha and IL-8 have been shown to be important
priming agents for CF neutrophils [42]. Recently we have shown
that AAT is localized to the neutrophil plasma membrane within
lipid rafts bound to CD16b (FcγRIIIb) and is released in com-
plex form (AAT:CD16b) by priming with sIC [25]. CD16b is
unique in that it is the only Fc receptor linked to the plasma
membrane by a GPI anchor and the metalloprotease ADAM-17
has been implicated in the shedding of CD16b. Within the pre-
sent study we show that priming of neutrophils in vitro with
IL-8 and TNF-alpha causes release of CD16b and AAT to the
extracellular milieu and in vivo, AAT:CD16b complex plasma
levels correlate strongly with these pro-inflammatory mediators.
Although antibiotic responsiveness in the absence of quanti-
tative cultures and serotype switching of bacterial species is
only suggestive of infective exacerbations, within our study
combination antibiotic treatment of individuals for an acute ex-
acerbation involving P. aeruginosa and/or S. aureus infection
resulted in an improvement in FEV1 in 8 of 10 patients tested.
In addition, the changes in plasma AAT:CD16b following anti-
biotic therapy suggested a direct association of plasma levels of
AAT:CD16b complex with a changing state of airway inflam-
mation and FEV1. Indeed, a soluble form of CD16b released
from neutrophils and bound to IgG [43] has previously been
detected in plasma. However, although the soluble CD16b con-
centration has been shown to increase at inflammatory sites
[43,44], a vigorous examination of its use as a plasma biomark-
er of inflammation or in the analysis of antibiotic efficiency has
not been previously performed. Moreover, the minimum level
of soluble CD16b detected by use of a monoclonal antibody
in normal serum was 7.3 nmol/L [43]. In contrast, the lowest
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These results suggest increased sensitivity of the dual ELISA
for detection of the complex biomarker compared to CD16b
on its own, possibly due to masking of antibody binding sites
within the protein complex. The present study is however not
without limitations. For example correlates of disease states be-
tween healthy controls, COPD, AATD and CF individuals are
not directly comparable since only patients with CF were in ex-
acerbation and only a proportion of these patients had before
and after samples of plasma analyzed. Moreover, data indicate
that a fraction of the patients with CF would be indistinguish-
able from the other groups when plasma AAT:CD16b complex
is used as a sole marker of exacerbation. However, in support of
the use of AAT:CD16b as an indicator of response, proteomic
and Western blot analysis of patient neutrophil plasma mem-
branes pre- and post-antibiotic treatment revealed increased
membrane bound expression of both AAT and CD16b post
treatment. Moreover, in this study we have developed a novel
microplate-based protein binding assay employing the use of
two antibodies raised against AAT and CD16b which allows
for rapid screening of multiple serum samples for AAT:
CD16b interactions. This method measures a precise protein–
protein interaction, utilizes relatively small amounts of patient
sample, is free of protein modification and does not require spe-
cialized instrumentation. Thus the clinical benefit of introduc-
ing the described AAT:CD16b protein binding assay as an
effective tool for evaluating pulmonary exacerbations is appar-
ent. Conversely however, the cost-effectiveness in terms of
health quality gained versus cost of implementation requires
further evaluation.
In conclusion, primed neutrophils have been found in pe-
ripheral blood during an exacerbation of CF, an observation
now supported by our study and the identification of circulating
levels of AAT:CD16b. Upon treatment of an exacerbation plas-
ma levels of AAT:CD16b complex decrease significantly, cor-
relating with an improvement in FEV1. These observations
illustrate that the expression of neutrophil priming-associated
biomarkers in peripheral blood can be used as read out for the
inflammatory process in CF. The AAT:CD16b biomarker
may be of benefit to clinical trials determining if drugs-in-
process are effective against inflammation and may also be-
come an extremely useful addition to the clinical diagnosis of
exacerbations and management of CF.Acknowledgments
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